Quick Answer
PTC THERAPEUTICS, INC. reported Revenue (ASC 606) of $1.73 billion for fiscal year 2025.
PTC THERAPEUTICS, INC. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $1.73B | +114.5% |
| 2024 | $806.78M | -14.0% |
| 2023 | $937.82M | +34.2% |
| 2022 | $698.80M | +29.7% |
| 2021 | $538.59M | +41.4% |
| 2020 | $380.77M | +24.0% |
| 2019 | $306.98M | +16.0% |
| 2018 | $264.73M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $211.01M | +7.2% | +18.0% |
| June 30, 2025 | $178.88M | -4.2% | -84.8% |
| March 31, 2025 | $1.18B | +459.7% | +497.7% |
| September 30, 2024 | $196.79M | +0.1% | +5.4% |
| June 30, 2024 | $186.70M | -12.7% | -11.1% |
| March 31, 2024 | $210.12M | -4.7% | +6.9% |
| September 30, 2023 | $196.58M | -9.5% | -8.1% |
| June 30, 2023 | $213.81M | +29.2% | -3.0% |
- PTC THERAPEUTICS, INC. showed an increase of +114.5% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2018–2025 period, PTC THERAPEUTICS, INC.’s revenue (asc 606) has grown by 553.7% (from $264.73 million to $1.73 billion).
- The most recent figure is from PTC THERAPEUTICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: